Published Date: 08 Mar 2023
Interventions to improve clinical practice increased the odds that people with type 2 diabetes and heart disease were prescribed the drugs recommended in our study by more than 100%.
Read Full NewsFindings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.
Here's some of what is coming soon to NeurologyLive® this week.
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.
5 Pulmonology Headlines You Missed in November 2025
Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43
Stage 5 CKD May Reverse Female Survival Advantage
1.
Aster Whitefield Hospital, with 506 beds, opened.
2.
Slowdown in progress found with cancer survival in England and Wales
3.
Children with rare gliomas have new hope thanks to clinical trial results.
4.
FDA Expands Approval of Osimertinib in Lung Cancer
5.
AI innovation unlocks non-surgical way to detect brain cancer spread
1.
Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"
2.
Uncovering the Hidden Gallons: How Much Blood Is Inside the Human Body?
3.
The Significance of APTT Blood Test Results for Detecting Coagulation Disorders
4.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
5.
Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
3.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
5.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation